What is the appropriate management for a Hodgkin lymphoma patient who, on day 6 after dengue infection, presents with a post‑viral exanthematous rash and high‑grade fever?

Management of Post-Dengue Exanthematous Rash with High-Grade Fever in Hodgkin Lymphoma Patient

This Hodgkin lymphoma patient presenting with high-grade fever and exanthematous rash on day 6 post-dengue requires immediate evaluation for secondary hemophagocytic lymphohistiocytosis (HLH) and bacterial superinfection, with urgent measurement of ferritin, fibrinogen, triglycerides, and complete blood count to guide potentially life-saving immunosuppressive therapy.

Critical Diagnostic Priorities

The convergence of dengue infection and underlying hematologic malignancy creates a uniquely high-risk scenario. Recent evidence demonstrates that patients with hematological malignancies, particularly Hodgkin lymphoma, experience significantly more severe dengue manifestations with warning signs occurring in 71% of post-transplant patients versus 22% in non-transplant hematology patients 1. While your patient hasn't undergone transplant, the immunosuppression from Hodgkin lymphoma itself creates similar vulnerability.

Immediate Laboratory Assessment Required

Obtain these specific tests urgently:

• Serum ferritin (HLH threshold: >500 μg/L, but dengue-HLH often shows extreme elevation >10,000 μg/L) 2, 3, 4
• Complete blood count with differential (look for progressive cytopenias beyond dengue-expected thrombocytopenia)
• Fibrinogen level (hypofibrinogenemia <150 mg/dL suggests HLH) 5
• Triglycerides (>265 mg/dL supports HLH)
• Liver transaminases (marked transaminitis disproportionate to dengue alone)
• D-dimer and coagulation profile (assess for DIC)
• Blood cultures (rule out bacterial sepsis in immunocompromised host)

The HLH Differential: A Life-Threatening Consideration

Dengue-associated HLH is rare but carries high mortality if untreated, and the clinical overlap with severe dengue creates diagnostic confusion 2, 4. The persistent high-grade fever on day 6—when dengue fever typically defervesces—is a critical red flag.

HLH Diagnostic Criteria (Need 5 of 8)

1. Fever ≥38.5°C
2. Splenomegaly
3. Cytopenia (≥2 lineages)
4. Hypertriglyceridemia and/or hypofibrinogenemia
5. Hemophagocytosis in bone marrow/spleen/lymph nodes
6. Low/absent NK cell activity
7. Ferritin ≥500 μg/L
8. Elevated soluble IL-2 receptor

If ferritin is >10,000 μg/L with progressive cytopenias and hypofibrinogenemia, strongly consider empiric dexamethasone 10 mg/m² IV daily while awaiting bone marrow biopsy 3, 4. The recent successful use of tocilizumab (IL-6 receptor blocker) in dengue-HLH represents an emerging option for refractory cases 3.

Alternative Diagnosis: Drug Hypersensitivity or Bacterial Infection

The exanthematous rash could represent:

• Drug reaction (if patient received antibiotics, antivirals, or other medications during dengue illness)
• Secondary bacterial infection (particularly concerning given immunosuppression from Hodgkin lymphoma)
• Post-viral exanthem (benign, but diagnosis of exclusion in this high-risk patient)

Specific Clinical Examination Points

• Rash morphology: Maculopapular with desquamation suggests post-dengue convalescent rash (typically appears day 4-7, benign). Petechial or purpuric elements suggest ongoing coagulopathy or HLH.
• Mucous membrane involvement: Suggests drug reaction (DRESS syndrome) or severe systemic process
• Hepatosplenomegaly: Palpate carefully—splenomegaly supports HLH
• Lymphadenopathy: Assess for Hodgkin lymphoma progression versus reactive changes

Management Algorithm

If Ferritin >10,000 μg/L + Progressive Cytopenias + Hypofibrinogenemia:

1. Start dexamethasone 10 mg/m² IV daily immediately 3, 4
2. Urgent bone marrow biopsy to confirm hemophagocytosis
3. Hematology consultation for consideration of etoposide-based HLH protocol if no response in 48-72 hours
4. Consider tocilizumab 8 mg/kg IV if refractory to corticosteroids 3

If Ferritin <10,000 μg/L but Clinical Deterioration:

1. Broad-spectrum antibiotics (e.g., piperacillin-tazobactam) given immunocompromised status
2. Hold any potentially causative medications
3. Supportive care: IV fluids cautiously (dengue patients risk fluid overload), platelet transfusion if <20,000/μL with bleeding
4. Serial ferritin and CBC every 12-24 hours to detect evolving HLH

If Stable with Benign-Appearing Rash:

1. Symptomatic management: Antihistamines, emollients
2. Close monitoring: Daily CBC, ferritin every 2-3 days for one week
3. Fever workup: If fever persists >48 hours, escalate to bacterial infection workup

Critical Pitfalls to Avoid

Do not attribute all findings to "severe dengue" in a Hodgkin lymphoma patient. The mortality data is sobering: 6% overall mortality in hematologic malignancy patients with dengue, with both deaths directly attributable to dengue complications 6. Male sex, prior hematopoietic stem cell transplantation, and platelet count <20,000/μL independently predict dengue warning signs 1.

Do not delay corticosteroids if HLH is suspected. The case reports consistently demonstrate that early dexamethasone initiation prevents progression to full cytokine storm and improves survival 2, 3, 4, 5. Waiting for bone marrow confirmation can be fatal.

Do not assume the rash is benign without excluding infection. Immunocompromised patients can develop atypical presentations of bacterial sepsis, fungal infections, or viral reactivations (CMV, EBV, HSV).

Monitoring Parameters

• Daily: Temperature curve, complete blood count, clinical examination
• Every 48 hours: Ferritin, liver enzymes, coagulation studies
• Weekly: If stable and improving, can space to weekly monitoring for 4 weeks post-dengue

The provided Hodgkin lymphoma guidelines 7, 8, 9 focus on lymphoma treatment protocols but do not address infectious complications in detail, highlighting the need to integrate general infectious disease and hematology principles in this complex scenario.